CLDF Title
Home | Contact Us | Bookmark
NASH HCC LiverQ Academy
Centers of Educational Expertise  
Live CME Events Webcasts Slide Library Abstract Library CLDF 2019 Year in Review Conference Highlights
Reuters Health Information: Viking shares surge after fatty liver drug trial

Viking shares surge after fatty liver drug trial

Last Updated: 2018-09-18

By Tamara Mathias

(Reuters) - Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals.

Viking said it plans to develop its VK2809 drug, a liver-selective thyroid receptor beta agonist, as a treatment for non-alcoholic steatohepatitis (NASH).

"While we acknowledge all the caveats associated with cross-trial comparison ... we believe VK2809 achieved numerically better results than Madrigal's MGL-3196," said Andy Hsieh at William Blair.

With regard to the primary endpoint, more patients receiving VK2809 had reductions in LDL-C of 20% or more, compared with placebo-treated patients. VK2809-treated patients also had statistically significant improvements in other lipids.

Depending on the dose, patients given VK2809 saw a median reduction of 57 to 60 percent in liver fat, compared to a median reduction of 9 percent in the placebo group. And 83 percent of patients given VK2809 had at least a 30 percent reduction in liver fat, compared to 18 percent of patients given placebo.

The results appeared to exceed those from all other oral drugs currently in development for NASH, Viking said.

The positive data could potentially shorten the length and size of future trials, Viking Chief Executive Brian Lian said.

"We do have some flexibility, given the potency here. We wouldn't have to do 5,000 patients or something," Lian said on a conference call with analysts.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2021 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.